Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Financing Activities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Cash from Financing Activities for 13 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 308.49% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.2 million through Dec 2025, down 30.08% year-over-year, with the annual reading at -$3.2 million for FY2025, 30.08% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$1.5 million at Theravance Biopharma, down from -$400000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $105.3 million in Q2 2021, with the low at -$701.8 million in Q3 2022.
  • Average Cash from Financing Activities over 5 years is -$43.6 million, with a median of -$1.5 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities soared 5521.2% in 2021, then plummeted 57728.57% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $149000.0 in 2021, then plummeted by 37456.38% to -$55.7 million in 2022, then surged by 45.01% to -$30.6 million in 2023, then surged by 98.81% to -$365000.0 in 2024, then crashed by 308.49% to -$1.5 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$1.5 million, -$400000.0, and -$503000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.